4.64
+0.2953(+6.80%)
Currency In USD
| Previous Close | 4.34 |
| Open | 4.41 |
| Day High | 4.66 |
| Day Low | 4.35 |
| 52-Week High | 5.15 |
| 52-Week Low | 1.34 |
| Volume | 1.23M |
| Average Volume | 1.75M |
| Market Cap | 558.99M |
| PE | -8.28 |
| EPS | -0.56 |
| Moving Average 50 Days | 4.26 |
| Moving Average 200 Days | 3.07 |
| Change | 0.3 |
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 03, 2026 12:00 PM GMT
WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday Ma
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiat
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company wi